A Phase II Trial of Sorafenib and Erlotinib in Unresectable Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2014
At a glance
- Drugs Erlotinib (Primary) ; Sorafenib (Primary)
- Indications Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- 27 Sep 2012 Planned end date changed from 1 May 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
- 27 Sep 2012 Last checked against ClinicalTrials.gov record.
- 26 May 2011 Planned End Date changed from 1 Jun 2015 to 1 May 2012 as reported by ClinicalTrials.gov.